Blinding, and Why You May Not Be Told

Part of Understanding Cancer Trials: Randomization and placebo.

About 3 minutes. Free, in your language, no account needed.

This is general education about clinical research — not medical advice, and not a way to join a study. Talk to your own doctor about your situation.

In some studies, people are not told which arm they are in. This is called blinding, and it is sometimes called masking.

The different kinds

• Open-label — everyone knows. You know, and your study doctor knows.
• Single-blind — you are not told, but the team is.
• Double-blind — neither you nor the study doctor knows.

Which one a study uses is written in the protocol and should be explained during consent, before anything is decided.

Why it is done

Knowing which treatment someone is receiving changes how things are reported and judged, even when everyone is being honest.

If you knew you were on the new treatment, you might notice and report symptoms differently. If your doctor knew, they might grade a side effect slightly differently, or order a scan sooner, or interpret a borderline scan one way rather than another. None of that is dishonesty. It is how human attention works.

Blinding removes that influence, so that what is measured is the treatment rather than everyone's expectations about the treatment.

When blinding is not possible

Blinding is often impossible in cancer studies, and researchers know it.

If two treatments are given in different ways, or have very visible and different side effects, or one involves surgery, then pretending nobody can tell would be a fiction. Many cancer studies are therefore open-label by design.

When that happens, studies use other ways to protect the result. A common one is having scans reviewed by radiologists who do not know which arm the person is in. This is sometimes called blinded independent review.

Being unblinded

Blinding is not absolute, and it is not more important than your safety.

There are written rules, agreed in advance, for when the information can be revealed. An urgent medical situation where knowing would change how you are treated is the clearest example. There is usually a process available at any hour to make that happen.

Blinding also normally ends when the study ends, and participants can usually be told which arm they were in.

Two questions that are fair to ask about any blinded study:

• What is the process for unblinding in an emergency, and who can do it?
• Will I be told which arm I was in when the study is over, and roughly when?

In short

• Blinding means not being told which arm you are in, so that expectations do not affect what is measured.
• Double-blind means neither you nor your study doctor knows.
• Many cancer studies cannot be blinded, and use blinded independent review of scans instead.
• Written rules exist for unblinding in an emergency, and blinding normally ends when the study ends.